Fluor assisted VaxGen through value engineering and constructability, as well as process facility integration technology, to reduce the overall cost of the project.
At the first site, in Incheon, South Korea, Fluor provided conceptual and preliminary engineering services for a facility capable of manufacturing at least 200 million doses annually of VaxGen's investigational AIDS vaccine. The facility, built on a 23-acre site, was owned by Celltrion Inc., a joint venture between VaxGen and a group of South Korean investors. The facility included capacity for the manufacture of additional biopharmaceutical products, either from VaxGen or other companies.
At the second site, in San Francisco, Fluor performed engineering, procurement, construction management and validation services for the 13,000-square-foot pilot plant facility. The facility was capable of producing up to 10 million doses per year of the vaccine candidate.